Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. (Q53544370)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

F Goutorbe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Goutte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A-L Boucher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

B Pereira

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

G Bommelaer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Buisson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

7 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

Journal of Crohn's and Colitis

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1113-1119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

The natural history of adult Crohn's disease in population-based cohorts

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Impact of disease location on fecal calprotectin levels in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV150

21 January 2018

Identifiers

DOI

10.1093/ECCO-JCC/JJV150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26351383%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference